Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Sea Limited (SE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Sea Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Sea Limited trades at $105.05 (market cap $63.84B). The key difference: Sea Limited is far larger — about 14.2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | SE | |
|---|---|---|
Market Cap | $4.49B | $63.84B |
Sector | Health | Media |
52-Week High | $28.06 | $196.50 |
52-Week Low | $20.06 | $78.16 |
Enterprise Value | $3.69B | $56.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Sea Limited (SE) trades at $104.23, up 0.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarters have mixed earnings performance. Analyst consensus remains strongly positive with a $131 price target, supported by improving cash flow trends and expanding profitability.
The outlook for SE is favorable given robust growth in its digital ecosystem and positive analyst sentiment, but risks include competitive pressures in Southeast Asian markets and potential volatility from earnings misses. Investors should weigh the high P/E ratio of 41.34 against the company's accelerating top-line expansion and margin improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
